TG Therapeutics, Inc. (LON: 0VGI)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 3.40B |
| Revenue (ttm) | 197.56M |
| Net Income (ttm) | -10.72M |
| Shares Out | n/a |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,142 |
| Average Volume | 3,845 |
| Open | 29.80 |
| Previous Close | 30.01 |
| Day's Range | 28.90 - 30.25 |
| 52-Week Range | 6.47 - 35.58 |
| Beta | n/a |
| RSI | 44.55 |
| Earnings Date | Feb 28, 2025 |
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral i... [Read more]
News
TG Therapeutics: 2025 Revenues Will Smash Expectations
TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade)
TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic developments, including a...
What's Going On With TG Therapeutics Stock Tuesday?
TG Therapeutics Inc (NASDAQ: TGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024 . What Happened: TG Therapeutics issued preliminary U....
TG Therapeutics says 2024 Briumvi sales topped expectations
TG Therapeutics Inc (TGTX) Announces Strong Preliminary Revenue for BRIUMVI in 2024
TG Therapeutics Inc (TGTX) Announces Strong Preliminary Revenue for BRIUMVI in 2024
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
TG Therapeutics Inc (TGTX) to Present at J.P. Morgan Healthcare Conference
TG Therapeutics Inc (TGTX) to Present at J.P. Morgan Healthcare Conference
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 43rd An...
20 stocks likely to lag the S&P 500 over the next year — for this one reason
Difficult-to-short stocks often trade at artificially inflated, unsustainable prices.
This Is What Whales Are Betting On TG Therapeutics
Investors with a lot of money to spend have taken a bearish stance on TG Therapeutics (NASDAQ: TGTX). And retail traders should know. We noticed this today when the trades showed up on publicly avail...
TG Therapeutics to Participate in the Evercore HealthCONx Conference
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing techno...
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in...
TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell
TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal...
TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - C...
FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics
Holly Springs, North Carolina site to provide security of supply for B-cell therapy for relapsing multiple sclerosis Holly Springs, North Carolina site to provide security of supply for B-cell therapy...
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the...
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's co...
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can...
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3 ...
TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, a...
TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercializ...
HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics
STAMFORD, Conn.--(BUSINESS WIRE)--HealthCare Royalty (“HCRx”), in conjunction with funds managed by Blue Owl Capital (“Blue Owl”), has entered into a $250 million term loan facility (the “Initial Term...
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the s...